Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides (NCT05838599)
π©Ί Plain-English Summary (8th-Grade Level)
Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more advanced skin disease. Imiquimod stimulates a Th1 lymphocyte response with increased IL-2 and IFN-Ξ±, but also induces IFN-Ξ±, TNF-Ξ±, IL-1Ξ±, IL-6, and IL-8, thereby bridging both innate and adaptive immunity. Dosing of both radiotherapy (RT) and imiquimod are based on standard-of-care doses/frequencies for CTCL. The reason imiquimod topical is given for a week before giving RT is to prime innate immune activity for when RT is delivered. It is believed that this serves as an adjuvant for the CD8+ antitumor response generated by RT. The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF.
Who can join: Review the eligibility criteria below.
Location: Northwestern University Department of Dermatology β Chicago, Illinois
Age range: 18 Years to 90 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Northwestern University Department of Dermatology β Chicago, Illinois
π Contact the Study Coordinator
Phone: (312) 503-5944
Email: NUderm-research@northwestern.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mycosis Fungoides
- Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or SΓ©zary Syndrome β Basking Ridge, New Jersey
- Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and SΓ©zary Syndrome β St Louis, Missouri
- A Study of VG712 in Patients With Mycosis Fungoides β Tampa, Florida
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides β Baltimore, Maryland
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome β Duarte, California
Explore by condition: All Mycosis Fungoides clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.